Buserelin


Generic Medicine Info
Contraindications
Undiagnosed vaginal bleeding (when indicated for endometriosis or pituitary desensitisation); tumours that are insensitive to hormone manipulation or after surgical removal of testes (when indicated for prostatic carcinoma). Pregnancy and lactation.
Special Precautions
Patient with polycystic ovarian syndrome, depression, hypertension, diabetes, history of or risk factors for QT prolongation, risk factors for osteoporosis. Not indicated for use in post-menopausal women. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Pituitary desensitisation: Perform pregnancy test prior to initiation of treatment. Prostate cancer: Serum testosterone levels, prostate-specific antigen, prostatic acid phosphatase, bone scan, signs/symptoms of obstructive uropathy, digital rectal exam, ECG (in patients at risk for QT prolongation), serum electrolytes. Endometriosis: Serum estradiol levels. Assess patient's CV risk and for signs or symptoms of depression.
Adverse Reactions
Significant: Depression or exacerbation of existing depression, prolonged QT interval, decreased bone density, anaemia, hypogonadism, pituitary adenomas, ovarian cyst, hypersensitivity reactions (e.g. rash, redness, itch, allergic asthma with dyspnoea, anaphylaxis; disease flare, neurological sequelae, thrombosis, CV disease, impaired micturition, hydronephrosis, lymphostasis, bone pain (when indicated for prostatic carcinoma). Blood and lymphatic system disorders: Rarely, leucopenia, thrombocytopenia. Cardiac disorders: Palpitations. Ear and labyrinth disorders: Tinnitus, hearing disorders. Eye disorders: Impaired vision, dry eyes, feeling of pressure behind the eyes. Gastrointestinal disorders: Constipation or diarrhoea, nausea, vomiting, lower abdominal pain, increased thirst. General disorders and administration site conditions: Tiredness, local injection site reactions. Investigations: Increased or decreased weight, increased serum liver enzyme and bilirubin levels. Metabolism and nutrition disorders: Appetite changes. Musculoskeletal and connective tissue disorders: Musculoskeletal pain or discomfort. Nervous system disorders: Dizziness, drowsiness, headache, paraesthesia. Psychiatric disorders: Anxiety, emotional instability, mood changes, nervousness, disturbances in concentration, memory or sleep. Reproductive system and breast disorders: Menopausal-like symptoms (e.g. hot flushes, increased sweating, dry vagina, dyspareunia and loss of libido), vaginal discharge, breast tenderness, increased or decreased breast size, withdrawal or breakthrough bleeding; menstruation-like bleeding (nasal). Skin and subcutaneous tissue disorders: Acne, dry skin, increased or decreased scalp or body hair, splitting nails. Vascular disorders: Oedema of the face or extremities, hot flushes.
Drug Interactions
May reduce the effect of antidiabetic agents. Increased risk of QT prolongation with class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol,) antiarrhythmic agents, methadone, moxifloxacin, antipsychotics. Combined use with gonadotropins may increase the risk for ovarian hyperstimulation syndrome (OHSS) than the use of gonadotropins alone.
CIMS Class
Hormonal Chemotherapy / Trophic Hormones & Related Synthetic Drugs
ATC Classification
L02AE01 - buserelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on buserelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in